Small-Cap Biotech M&A, via the Internet
Robert Naismith, CEO of eMed Securities, a private investment banking firm, has just sold tiny, troubled American biotech firm Cistron to Celltech in the UK--via the Internet. Naismith put a lot of work into building a case that Cistron's science was good, even if its corporate history was less than sterling. Then he e-mailed letters tailored to different types of potential buyers and watched the information he'd posted on his firm's web site get 30,000 hits in the two weeks. EMed intends to keep on leveraging the Internet, not only to promote M&A of small-cap life science companies, but to help those firms attract retail capital. On-line roadshows are on the way, he says.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”